CombiGene and Cell and Gene Therapy Catapult sign agreement to develop manufacturing process for novel gene therapy to treat epilepsy

Jan 12, 2018

Collaboration between Cell and Gene Therapy Catapult (CGT Catapult) and Swedish gene therapy company CombiGene will take a unique therapy one step closer to helping sufferers of hard to treat epilepsy.
Read more >>

Nyheter och rapporter

New issue of CombiGenes Newsletter 15 March, 2018
Final data from long-term study of CombiGene’s epilepsy treatment indicate clearly positive effects in the form of fewer and shorter seizures. 19 February, 2018
CombiGene establishes UK subsidiary to secure close and effective collaboration with Cell and Gene Therapy Catapult 31 January, 2018
Year-end statement January-December 2017 29 January, 2018
CombiGene participates in Life Science Day, Wednesday 7 March 24 January, 2018
CombiGene AB (publ) presents the year-end statement for 2017 at an earlier date than planned 23 January, 2018
CombiGene’s board approves preferential rights issue 22 January, 2018

Combigene AB, Medicon Village, SE-223-81 Lund, Visiting adress: Scheelevägen 2, Lund, Sweden